dc.contributor.author | Jones, Heather | |
dc.contributor.author | Raymond, Warren David | |
dc.contributor.author | Eilertsen, Gro Østli | |
dc.contributor.author | Nossent, Johannes | |
dc.date.accessioned | 2019-05-15T09:07:45Z | |
dc.date.available | 2019-05-15T09:07:45Z | |
dc.date.issued | 2018-11-14 | |
dc.description.abstract | The erythropoietin receptor (EpoR) stimulates erythrocyte proliferation after erythropoietin binding. EpoR belongs to
the cytokine receptor superfamily and can be found on macrophages and endothelial cells. As there are no data on the
role of EpoR systemic autoimmune diseases, we investigated the role of soluble EpoR (sEpoR) in patients with systemic
lupus erythematosus (SLE). In a cross-sectional study we recorded clinical characteristics, disease activity (SLEDAI-2K)
and organ damage (SDI). sEpoR, autoantibodies and cytokines were measured by enzyme-linked immunosorbent assay
(ELISA) in SLE patients (n=100) and compared with a rheumatoid arthritis (RA) cohort (n=57) and a cohort with noninflammatory back pain (NIBP; n=89). Data were analysed with non-parametric techniques. We found no significant
difference in sEpoR levels across the SLE, RA and NIBP groups and sEpoR levels were similar in patients with (6% of SLE
and 31% of RA) or without anaemia. sEpoR levels were unrelated to haemoglobin levels, SLEDAI-2K or SDI scores, but
in both cohorts correlated with levels for C-reactive protein (CRP), interleukin-6 (IL-6), tumour necrosis factor (TNF)
and IL-1 (all <i>P</i><0.001). sEpoR levels are not involved in anaemia or erythropoietin resistance in SLE and RA patients, but
closely mirror the underlying inflammatory process. This suggests that increased shedding of sEpoR during inflammation
occurs at other sites than bone marrow. | en_US |
dc.description.sponsorship | Arthritis Foundation of WA | en_US |
dc.description | Source at <a href=https://doi.org/10.1177/2058739218811032>https://doi.org/10.1177/2058739218811032. </a> | en_US |
dc.identifier.citation | Jones, H., Raymond, W., Eilertsen, G. & Nossent, J. (2018). Soluble erythropoietin receptor levels associate with inflammatory mediators but not with disease activity or cumulative organ damage in patients with systemic lupus erythematosus. <i>European Journal of Rheumatology and Inflammation, 16</i>. https://doi.org/10.1177/2058739218811032 | en_US |
dc.identifier.cristinID | FRIDAID 1666952 | |
dc.identifier.doi | 10.1177/2058739218811032 | |
dc.identifier.issn | 0140-1610 | |
dc.identifier.uri | https://hdl.handle.net/10037/15311 | |
dc.language.iso | eng | en_US |
dc.publisher | SAGE Publications | en_US |
dc.relation.journal | European Journal of Rheumatology and Inflammation | |
dc.rights.accessRights | openAccess | en_US |
dc.subject | anaemia | en_US |
dc.subject | anaemia of chronic disease | en_US |
dc.subject | cytokine receptor | en_US |
dc.subject | disease activity | en_US |
dc.subject | erythropoietin | en_US |
dc.subject | erythropoietin receptor | en_US |
dc.subject | inflammation | en_US |
dc.subject | rheumatoid arthritis | en_US |
dc.subject | systemic lupus erythematosus | en_US |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710 | en_US |
dc.title | Soluble erythropoietin receptor levels
associate with inflammatory mediators
but not with disease activity or cumulative
organ damage in patients with systemic
lupus erythematosus | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |